BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19005469)

  • 1. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.
    Hurtado A; Holmes KA; Geistlinger TR; Hutcheson IR; Nicholson RI; Brown M; Jiang J; Howat WJ; Ali S; Carroll JS
    Nature; 2008 Dec; 456(7222):663-6. PubMed ID: 19005469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.
    Wang S; Somisetty VS; Bai B; Chernukhin I; Niskanen H; Kaikkonen MU; Bellet M; Carroll JS; Hurtado A
    Oncogene; 2020 Oct; 39(40):6300-6312. PubMed ID: 32843722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
    Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
    Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
    Higgins MJ; Stearns V
    Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
    [No Abstract]   [Full Text] [Related]  

  • 7. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
    Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
    Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
    J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.
    Chen B; Wang Y; Kane SE; Chen S
    J Mol Endocrinol; 2008 Nov; 41(5):367-77. PubMed ID: 18768663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
    Ross-Innes CS; Stark R; Teschendorff AE; Holmes KA; Ali HR; Dunning MJ; Brown GD; Gojis O; Ellis IO; Green AR; Ali S; Chin SF; Palmieri C; Caldas C; Carroll JS
    Nature; 2012 Jan; 481(7381):389-93. PubMed ID: 22217937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
    Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
    J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
    J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
    Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
    Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.
    Shibata T; Watari K; Izumi H; Kawahara A; Hattori S; Fukumitsu C; Murakami Y; Takahashi R; Toh U; Ito KI; Ohdo S; Tanaka M; Kage M; Kuwano M; Ono M
    Cancer Res; 2017 Jan; 77(2):545-556. PubMed ID: 27879270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis.
    Deblois G; Chahrour G; Perry MC; Sylvain-Drolet G; Muller WJ; Giguère V
    Cancer Res; 2010 Dec; 70(24):10277-87. PubMed ID: 20961995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Blockade of Activating
    Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity.
    Leung E; Kannan N; Krissansen GW; Findlay MP; Baguley BC
    Cancer Biol Ther; 2010 May; 9(9):717-24. PubMed ID: 20234184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.